51885-79-1

Basic information

• Product Name: 4-Ethyl-3-nitro-benzoic acid Methyl ester
• Synonyms: 4-Ethyl-3-nitro-benzoic acid Methyl ester;Methyl 4-Ethyl-3-Nitrobenzoate;Benzoic acid, 4-ethyl-3-nitro-, methyl ester
• CAS NO: 51885-79-1
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.19864
• EINECS: -0
• Mol File: 51885-79-1.mol

Chemical Properties

• Boiling Point: 314.6±30.0 °C(Predicted)
• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-Ethyl-3-nitro-benzoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethyl-3-nitro-benzoic acid Methyl ester(51885-79-1)
• EPA Substance Registry System: 4-Ethyl-3-nitro-benzoic acid Methyl ester(51885-79-1)

Safety Data

• Hazardous Substances Data: 51885-79-1(Hazardous Substances Data)

Upstream product

• 4748-80-5 4-ethyl-3-nitro-benzaldehyde 
• 124-41-4 sodium methylate 
• 103440-95-5 4-Ethyl-3-nitrobenzoic acid 
• 619-64-7 p-ethylbenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 702643-06-9 methyl 4-(2-hydroxy-1-methylethyl)-3-nitrobenzoate 
• 1449668-98-7 C₁₇H₁₈N₄O₂ 
• 201286-95-5 6-(methoxycarbonyl)-3-methyl-1H-indazole 
• 1039151-67-1 4-(1-bromoethyl)-3-nitrobenzoic acid methyl ester 
• 1619260-96-6 methyl 4-(1-methoxyethyl)-3-nitrobenzoate 
• 1619260-97-7 4-(1-methoxyethyl)-3-nitrobenzoic acid 
• 1619260-95-5 2,5-dioxopyrrolidin-1-yl 4-(1-methoxyethyl)-3-nitrobenzoate 
• 79481-75-7 4-acetyl-3-nitrobenzoic acid 
• 868211-93-2 methyl 4-ethyl-3-fluorobenzoate 
• 1427395-09-2 (3-chloro-4-ethylphenyl)methanol 
• 1081551-72-5 methyl 3-chloro-4-ethylbenzoate 
• 51885-91-7 methyl 4-ethyl-3-iodobenzoate 
• 88072-17-7 4-Ethyl-3-(2-oxo-azetidin-1-yl)-benzoic acid methyl ester 
• 88072-07-5 3-(3-Bromo-propionylamino)-4-ethyl-benzoic acid methyl ester 

Relevant articles and documents

SMALL MOLECULE MODULATORS OF HUMAN STING

The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

High-yielding and photolabile approaches to the covalent attachment of biomolecules to surfaces via hydrazone chemistry

The development of strategies to couple biomolecules covalently to surfaces is necessary for constructing sensing arrays for biological and biomedical applications. One attractive conjugation reaction is hydrazone formation - the reaction of a hydrazine w

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

New Types of Very Efficient Photolabile Protecting Groups Based upon the [2-(2-Nitrophenyl)propoxy]carbonyl (NPPOC) Moiety

Based upon the photolabile [2-(2-nitrophenyl)propoxy]carbonyl group (NPPOC), a large number of modified 2-(2-nitrophenyl)propanol derivatives substituted at the phenyl ring (see 23-34 and 57-76) as well as at the side-chain (see 85-92 and 95-98) were synthesized to improve the photoreactivity of this new type of photolabile entity. The phenyl moiety was also exchanged by the naphthalenyl group (see 102, 103, 105, 108, 110, 113, and 114), the thienyl substituent (see 115, 117, 118, and 120), and the benzothienyl substituent (see 121). The 2-(2-nitroaryl- and heteroaryl) propanols were converted with diphosgene into the corresponding carbonochloridates, which reacted subsequently with thymidine to the thymidine 5′-(protected carbonates) 123-178 as the main reaction products. In several cases, the corresponding 3′-carbonates and 3′,5′ -dicarbonates 179-212 were also isolated and characterized. Photolysis studies under standardized conditions (see Table) indicated that the rate of photocleavage varies in a broad range depending on the substituents. So far, the thymidine 5′-[2-(5-halo-2-nitrophenyl)propyl carbonates] 127-129, 5′-[2-(nitro[1,1′-biphenyl]3-yl)propyl carbonates] 136-139, 5′-{2-[2-nitro-5-(thianthren-1-yl)phenyl]propyl carbonate} (140), 5′-[2-(5-naphthalenyl-2-nitrophenyl)propyl carbonates] 141 and 142, and 5′-[2-(2-nitro-5-thienylphenyl)propyl carbonates] 143 and 144 showed the best properties regarding fast and uniform deprotection. Since the nucleobases of 213-215 do not influence the photocleavage features, in general, the new type of photolabile building blocks allows in form of their 3′ -phosphoramidites the photolithographic formation of high-quality biochips.

Method for inhibiting neoplastic cells with indole derivatives

A method for inhibiting neoplastic cells and related conditions by exposing them to substituted indole derivatives.